FDA Takes Further Steps to Confront Opioid Crisis Through Risk Evaluation and Mitigation Strategy Programs

The FDA took further steps to strengthen the transmucosal immediate-release fentanyl (TIRF) REMS program with approval of modifications that which will ensure that the benefits of these drugs continue to outweigh the risks.